The technology will be evaluated in refolding difficult to express microbial products that are expressed as inclusion bodies, under the agreement.
BaroFold CSO and Founder Matthew Seefeldt said, "Lonza is a pioneer in biologic drug manufacturing and to collaborate with them further enhances our ability to provide the global biotechnology arena with a novel refold technology."
As a part of the non-exclusive technology and licensing deal, Lonza will install PreEMT unit at its microbial development and manufacturing plant located in Switzerland and also has an option to extend the evaluation to GMP production analysis.
Lonza custom manufacturing development services business unit global head Janet White said, "This agreement allows us to evaluate BaroFold’s innovative high pressure refold technology as a complement to our existing XS Expression Technologies Platform, and offer customers a comprehensive toolbox for microbial recombinant protein production."